Controlled Substance Prescribing via Telehealth for HRT Clinics in 2026

Current as of November 3, 2026. An HRT clinic can sometimes prescribe testosterone after a telehealth visit without a prior in-person examination, but federal permission is only the first check. Testosterone is a federal Schedule III controlled substance. A valid workflow also depends on where the patient is during the visit, the prescriber's professional and controlled-substance authority, the state's telehealth rule, a legitimate medical purpose, and the prescription method. Connecticut, for example, generally prohibits Schedule III prescribing through telehealth for routine hormone therapy, even while a federal temporary flexibility exists. [1][2][3][9]

This guide is for US TRT and hormone-clinic operators and practitioners building a repeatable prescribing process. It follows one prescription from scheduling through pharmacy transmission and uses four verified state examples to show why a national yes-or-no answer is unreliable. It is not a treatment protocol or a 50-state survey.

Why testosterone needs a controlled-substance workflow

The federal Schedule III list names testosterone. That classification follows the drug; describing a service as HRT, BHRT, or virtual care does not remove controlled-substance requirements. Other medicines used in hormone care may have different classifications, so the clinic should identify the actual ingredient and formulation before choosing a prescribing route. [1]

Controlled-substance prescribing raises several distinct questions. May this clinician treat a patient in this state? May this clinician prescribe this scheduled drug? Does the visit satisfy the applicable in-person or telemedicine rule? Is the prescription clinically justified? Must it be sent electronically? A yes to one does not answer the others. A scheduling tool that permits a video visit, for example, does not establish DEA or state authority. [2][3][5][6]

The Ryan Haight Act normally ties a valid controlled-substance prescription dispensed by means of the internet to at least one in-person medical evaluation by the prescribing practitioner, subject to defined telemedicine exceptions. After that practitioner has evaluated the patient in person, the Act's specific prior-exam restriction is different for that relationship; the prescription still must be for a legitimate medical purpose and meet other federal and state requirements. A visit with a different clinician should not be treated as the prescriber's own prior examination without analyzing another applicable exception. [2][3][5]

What federal telemedicine rule applies in 2026

DEA and HHS's fourth temporary extension permits a DEA-registered practitioner to prescribe Schedule II through V controlled substances by telemedicine to a patient the practitioner has not examined in person, through the end of December 31, 2026, if all conditions in 21 CFR 1307.41 are met. The prescription must serve a legitimate medical purpose in the usual course of professional practice; the encounter must use the referenced interactive telecommunications system; the practitioner must have authority under the registration or an applicable exemption for the drug; and the prescription must comply with Part 1306. Other federal and state law still applies. [3][4]

For a new testosterone patient relying on that temporary route, use a live, two-way audio-video visit. DEA's narrower audio-only permission concerns specified FDA-approved narcotic Schedule III through V medicines for opioid-use-disorder treatment. It does not provide a general phone-only path for testosterone. A questionnaire, text thread, portal message, or ordinary call should not be documented as though it were the qualifying video encounter. [3][4]

The rule changes the federal prior-in-person issue for qualifying encounters. It does not approve a specific testosterone regimen, override a state that restricts remote controlled-substance prescribing, create a professional license, or excuse an inadequate assessment. The clinician remains responsible for deciding whether remote evaluation is appropriate for the patient and for recording the basis for each prescription. [3][5]

The current federal temporary rule does not impose a special 30-day initial testosterone limit. Prescription quantity, follow-up, and refills still require a clinical decision and compliance with federal and applicable state rules. [3][5]

Is DEA special registration available yet

DEA proposed a special-registration system in January 2025 for certain controlled-substance telemedicine prescribing without a prior in-person evaluation. The proposal included different registration categories, limited state telemedicine registrations, and added recordkeeping. Those are proposed terms, not an active application route for an HRT clinic. [7]

As of November 3, 2026, the federal regulatory review listing shows the special-registration action at the final-rule review stage with review pending. The published final text, effective date, and any transition period could differ from the proposal. A clinic should not promise patients that the proposal has already replaced the temporary rule. Monitor the Federal Register and DEA, then change intake and prescribing rules only after the binding text is published. [7][8]

The state rule can change the answer

The patient's physical location at the time of the appointment is a starting point for the state-law check. HHS explains that cross-state practice may require a full license, a compact privilege, reciprocity, a temporary-practice exception, or a telehealth registration, depending on the state and profession. The prescriber's home-state license and a patient's home address do not settle the question when the patient joins from somewhere else. [10]

The examples below were checked against official state sources. They illustrate different controls; they are not permissions for an individual prescription or substitutes for checking the current rule for every jurisdiction in a clinic's service area.

Connecticut requires a hard stop for routine virtual TRT prescribing

Connecticut General Statutes section 19a-906(c) says a telehealth provider may not prescribe a Schedule I, II, or III controlled substance through telehealth, except a Schedule II or III drug used in specified medication-assisted treatment or treatment of psychiatric disabilities or substance use disorders, with federal compliance. Routine testosterone replacement for hypogonadism does not fit those stated exceptions. A clinic should not schedule a Connecticut patient for a video-only testosterone prescribing pathway on the strength of the federal extension. Obtain jurisdiction-specific advice before building any alternative workflow. [1][9]

This is a useful test of national policies: an active DEA temporary rule can coexist with a more restrictive state telehealth rule. A pharmacy's ability to receive a prescription, or an EMR's ability to generate it, does not remove the state restriction. [3][9]

New York adds a telehealth exception and prescription controls

New York's controlled-substance regulation generally calls for an in-person medical evaluation before prescribing but lists a telemedicine or telehealth exception when consistent with state law and DEA rules. The state Department of Health also says practitioners must follow its Prescription Monitoring Program registry requirements for Schedule II, III, and IV drugs and its electronic-prescribing requirements. Testosterone's Schedule III status brings those controls into the workflow. [1][11][12]

For a New York patient, record the legal telemedicine path, the PMP review or a documented applicable exception, the prescriber's state authority, and the method used to issue the prescription. New York generally requires electronic prescribing, subject to its own exceptions. A clinician should not infer that federal permission to conduct the visit removes the state PMP or electronic-prescribing step. [11][12]

California requires a state license and CURES review

The Medical Board of California says a physician treating a patient located in California by telehealth generally needs a current California license. A limited out-of-state consultation exception does not let the consultant take ultimate authority for that patient's care. The Board applies the same standard of care to telehealth as to in-person care. [13]

California's CURES rule generally requires an authorized practitioner to consult the patient's controlled-substance history before first prescribing a Schedule II, III, or IV drug, subject to statutory exemptions, and at least every six months while the drug remains in the treatment plan. The Board specifies a current lookback timing for required checks. Because testosterone is Schedule III, a California TRT workflow should record the CURES event and any actual exception, not merely a checkbox labeled “PDMP complete.” [1][14]

Florida distinguishes telehealth registration from DEA authority

Florida allows qualified out-of-state clinicians to register to provide telehealth services to patients in Florida. Its Department of Health says that registration is for clinicians licensed outside Florida; an existing Florida licensee does not apply for the separate out-of-state registration. Florida's statute restricts telehealth prescribing of Schedule II drugs to specified circumstances. Testosterone is federally Schedule III, so that particular Schedule II limit is not the entire testosterone analysis. [1][15][16]

Florida's department also describes narrow exceptions to the out-of-state telehealth registration requirement, including emergency care and consultation with a Florida-licensed clinician who retains ultimate authority. Neither an exception nor a telehealth registration should be read as automatically supplying DEA registration, scope of practice, or every prescribing permission. Verify the prescriber's full arrangement before scheduling remote testosterone prescribing. [15][16]

Together, these examples suggest a practical state file: keep a link to the official rule, date checked, clinician type, patient location, telehealth permission, controlled-substance restrictions, professional-license requirement, monitoring-program step, electronic-prescribing rule, and any exception's exact scope. Update it when the state or federal rule changes. [9][10][11][13][15]

A prescription pathway an HRT clinic can audit

1. At scheduling, capture where the patient will actually be. Ask the patient to confirm their physical state before the visit and again when the video encounter starts. If it differs from the state used to assign the clinician, pause the controlled-substance pathway until the state file is checked. A mailing address or past visit location is not enough for a traveling patient. [10]

2. Match the prescriber to that location and drug. Verify the clinician's current professional license or telehealth authority, scope, relevant state controlled-substance permissions, DEA registration or exemption, and any delegation or supervision arrangement. Record who performed the check and which source was used. For a multi-state practice, have the compliance owner assess the applicable DEA registration arrangement rather than assuming one number covers every configuration. [3][10][16]

3. Select and document the visit path. Record whether the prescribing practitioner has previously examined this patient in person, is using the current temporary federal pathway, or is relying on another defined legal exception. If using the 2026 temporary pathway for a new testosterone patient, perform and document the live audio-video encounter. A staff intake may collect information, but it does not replace the clinician's legal and clinical work. [2][3][4]

4. Complete the clinical assessment. The clinician should review the information needed to decide whether testosterone is indicated, whether a remote assessment is sufficient, what follow-up is needed, and whether issuing a prescription has a legitimate medical purpose. This guide does not prescribe laboratory thresholds, doses, or monitoring intervals. The record should make the clinician's reasoning clear enough for another authorized clinician to understand the decision. [3][5]

5. Perform state checks before signing. Depending on the state, this may include a prescription monitoring program review, telehealth consent, identity or location documentation, electronic-prescribing mandate, or a state-specific restriction. Record the time and result of the check, and document the basis for any exception. California's CURES and New York's PMP requirements show why a single generic “controlled drug” task can miss different state steps. [11][12][13][14]

6. Sign and transmit through the correct route. Part 1306 governs the underlying controlled prescription. If it is sent electronically, Part 1311 governs the EPCS application and signing process, including the practitioner's two-factor authentication. A staff member may help enter information where the rule permits, but the individual practitioner signs the electronic controlled prescription. State mandates can require an electronic route even though federal EPCS rules do not impose one national mandate for every prescription. [5][6]

7. Reconcile the result. Check whether the prescription was transmitted and accepted, retain the signed record, and resolve failed transmissions before sending another prescription. Avoid a duplicate when a pharmacy reports delay rather than rejection. Record the reason and legal basis if an outage route or state electronic-prescribing exception is used. The clinical decision, electronic signature, pharmacy status, and exception record should be retrievable together. [5][6]

For a vendor demonstration, use a de-identified journey that includes a patient moving states, a prescriber with multiple locations, a video visit, a required monitoring-program check, and a failed transmission. Ask the vendor to show the exact version and connected EPCS component it would deploy, plus the underlying Part 1311 audit or certification evidence. Do not assume a general electronic-prescribing feature is a compliant controlled-substance signing system. [6]

Refills and follow-up are separate decisions

Under the federal rule for Schedule III and IV drugs, a prescription may not be filled or refilled more than six months after issuance and may not be refilled more than five times. These are outside limits on the prescription's refill life, not a clinical recommendation for how often an HRT patient should be seen or a guarantee that a state permits every refill. A new prescription needs its own legitimate medical purpose and current authority. [5][17]

An HRT clinic can use a renewal queue to surface the last clinical review, patient location, state monitoring-program date, prescription issue date, remaining authorized refills, and the prescriber's license and registration status. If the patient has relocated, the new state check belongs before renewal. If a new prescriber takes over, verify that clinician's own legal and clinical basis instead of inheriting a prior prescriber's in-person visit as a universal Ryan Haight shortcut. [2][10][17]

What should change before the end of 2026

The present federal extension expires at the end of December 31, 2026. That date is a planning trigger, not proof that every patient will need an office visit on January 1, 2027. The special-registration rule remains under review and could be published with different conditions or a different effective date. [3][8]

Inventory patients whose testosterone prescriptions depend on the no-prior-in-person temporary pathway. For each, record the prescriber, patient state, next visit, expected prescription date, and feasible in-person evaluation option if the legal route changes. Assign a person to watch DEA and the Federal Register, and update patient communications only from the final published rule. [3][8]

For the prescription system itself, see the EPCS guide for HRT clinics and the testosterone EPCS practitioner guide. If you are evaluating WealMD, request a demonstration using your actual states, clinician types, and controlled-prescribing scenario; ask the team to verify each claimed capability in the version offered to your clinic.

Frequently asked questions

Can a clinic prescribe testosterone by video in every state

No. Federal law permits a qualifying telemedicine path through December 31, 2026, but states can add stricter limits. Connecticut's Schedule III telehealth restriction is an example that matters to routine TRT. Check the patient location, clinician authority, drug, and state rule before treating the visit as eligible. [1][3][9]

Does a prior in-person visit with another clinician solve the Ryan Haight issue

Do not assume so. The statute and DEA's explanation focus on an in-person medical evaluation by the prescribing practitioner for that particular route. A clinic using another exception should identify and document it rather than treating a colleague's exam as interchangeable. [2][3]

Is a state telehealth registration the same as DEA special registration

No. Florida's out-of-state telehealth registration is a state professional-practice route. DEA's proposed special registration is a federal controlled-substance framework that is still under review as of November 3, 2026. Neither should be substituted for checking the other authorities that apply to the prescription. [8][15][16]

Does EPCS make a telehealth testosterone prescription legal

EPCS is the electronic signing and transmission route for a controlled prescription. It cannot cure a prohibited telehealth encounter, an unauthorized prescriber, or a prescription without a legitimate medical purpose. The visit, prescriber authority, clinical decision, state rules, and EPCS process all need to stand on their own. [3][5][6][9]

Sources

1. eCFR, 21 CFR 1308.13, Schedule III, current text. Official source
2. US Code, 21 USC 829(e), controlled substances dispensed by means of the internet. Official source
3. eCFR, 21 CFR 1307.41, temporary telemedicine flexibilities, current text. Official source
4. DEA, Fourth Temporary Extension press release, December 31, 2025. Official source
5. eCFR, 21 CFR Part 1306, prescriptions, current text. Official source
6. eCFR, 21 CFR Part 1311, electronic prescriptions, current text. Official source
7. Federal Register, Special Registrations for Telemedicine and Limited State Telemedicine Registrations, proposed rule, January 17, 2025. Official source
8. OMB Office of Information and Regulatory Affairs, pending review of RIN 1117-AB40, accessed November 3, 2026. Official source
9. Connecticut General Assembly, 2026 supplement, section 19a-906(c). Official source
10. HHS, Licensing across state lines. Official source
11. New York State Department of Health, 10 NYCRR section 80.63, effective May 21, 2025. Official source
12. New York State Department of Health, Bureau of Narcotic Enforcement, controlled-substance prescribing and PMP. Official source
13. Medical Board of California, Telehealth. Official source
14. Medical Board of California, CURES Mandatory Use. Official source
15. Florida Legislature, 2026 Florida Statutes, section 456.47. Official source
16. Florida Department of Health, Out-of-State Telehealth Provider FAQs. Official source
17. eCFR, 21 CFR 1306.22, Schedule III and IV refills, current text. Official source